Yungan TAO
@yg_tao
Radiation Oncologist, Gustave Roussy Cancer Campus
President-Elect GORTEC - French Head and Neck Oncology Radiotherapy Group
ID: 788133896093372416
17-10-2016 21:45:38
256 Tweet
354 Followers
318 Following
Big PFS gain with HR 0.51 in favor of Ivonescimab (AK112) vs Pembro 1L NSCLC compared with HR 0.78 in LEAP-007 Pembrolizumab +/- Lenvatinib, could we expect OS gain? Hope AK112 also in HNSCC Pierre Blanchard, MD